TWI838531B - 索吡銨溴化物的結晶形態及其製造方法 - Google Patents

索吡銨溴化物的結晶形態及其製造方法 Download PDF

Info

Publication number
TWI838531B
TWI838531B TW109117164A TW109117164A TWI838531B TW I838531 B TWI838531 B TW I838531B TW 109117164 A TW109117164 A TW 109117164A TW 109117164 A TW109117164 A TW 109117164A TW I838531 B TWI838531 B TW I838531B
Authority
TW
Taiwan
Prior art keywords
compound
crystalline form
content
crystalline
bromide
Prior art date
Application number
TW109117164A
Other languages
English (en)
Chinese (zh)
Other versions
TW202110796A (zh
Inventor
丸林千能
渡辺将仁
赫伯特 Ｒ 布林曼
Original Assignee
日商科研製藥股份有限公司
美商布里克爾生技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商科研製藥股份有限公司, 美商布里克爾生技公司 filed Critical 日商科研製藥股份有限公司
Publication of TW202110796A publication Critical patent/TW202110796A/zh
Application granted granted Critical
Publication of TWI838531B publication Critical patent/TWI838531B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/147—Saturated compounds having only one carboxyl group and containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW109117164A 2019-05-23 2020-05-22 索吡銨溴化物的結晶形態及其製造方法 TWI838531B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851880P 2019-05-23 2019-05-23
US62/851,880 2019-05-23

Publications (2)

Publication Number Publication Date
TW202110796A TW202110796A (zh) 2021-03-16
TWI838531B true TWI838531B (zh) 2024-04-11

Family

ID=72146250

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109117164A TWI838531B (zh) 2019-05-23 2020-05-22 索吡銨溴化物的結晶形態及其製造方法
TW112144978A TWI870116B (zh) 2019-05-23 2020-05-22 索吡銨溴化物的結晶形態及其製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112144978A TWI870116B (zh) 2019-05-23 2020-05-22 索吡銨溴化物的結晶形態及其製造方法

Country Status (18)

Country Link
US (3) US20220298108A1 (https=)
EP (1) EP3972955A4 (https=)
JP (2) JP6748329B1 (https=)
KR (1) KR20220011671A (https=)
CN (1) CN114008023B (https=)
AU (1) AU2020277881B2 (https=)
BR (1) BR112021023241A2 (https=)
CA (1) CA3139948A1 (https=)
CL (1) CL2021003047A1 (https=)
CO (1) CO2021017456A2 (https=)
IL (1) IL288285B1 (https=)
MX (1) MX2021014163A (https=)
MY (1) MY206154A (https=)
PH (1) PH12021552915A1 (https=)
SG (1) SG11202111678WA (https=)
TW (2) TWI838531B (https=)
WO (1) WO2020235665A1 (https=)
ZA (1) ZA202109514B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI870116B (zh) * 2019-05-23 2025-01-11 日商科研製藥股份有限公司 索吡銨溴化物的結晶形態及其製造方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4213158A1 (en) 2020-11-13 2023-07-19 Ahead Biocomputing, Co. Ltd Information processing device, information processing method, recording medium recording information processing program, and information processing system
CN115925603B (zh) * 2022-11-29 2025-07-22 山东齐都药业有限公司 索吡溴铵的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059021A1 (en) * 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic zwitterions
WO2018026869A1 (en) * 2016-08-02 2018-02-08 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
ATE529399T1 (de) * 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
MX357741B (es) * 2012-07-06 2018-07-23 Laboratorios Senosiain S A De C V Star Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
US9512166B2 (en) * 2012-09-05 2016-12-06 Amri Ssci, Llc Cocrystals of progesterone
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
US10282282B2 (en) * 2016-06-29 2019-05-07 Synopsys, Inc. Automated HTTP user flows simulator
US20220298108A1 (en) * 2019-05-23 2022-09-22 Kaken Pharmaceutical Co., Ltd. Crystalline form of sofpironium bromide and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059021A1 (en) * 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic zwitterions
WO2018026869A1 (en) * 2016-08-02 2018-02-08 Dermira, Inc. Processes for making, and methods of using, glycopyrronium compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI870116B (zh) * 2019-05-23 2025-01-11 日商科研製藥股份有限公司 索吡銨溴化物的結晶形態及其製造方法

Also Published As

Publication number Publication date
JP2020189856A (ja) 2020-11-26
IL288285B1 (en) 2026-02-01
TW202110796A (zh) 2021-03-16
CA3139948A1 (en) 2020-11-26
SG11202111678WA (en) 2021-11-29
US20210395197A1 (en) 2021-12-23
JP2020189839A (ja) 2020-11-26
AU2020277881A1 (en) 2021-12-09
CN114008023A (zh) 2022-02-01
ZA202109514B (en) 2023-12-20
US11566000B2 (en) 2023-01-31
CL2021003047A1 (es) 2022-09-20
AU2020277881B2 (en) 2025-03-06
CO2021017456A2 (es) 2022-01-17
US11584715B2 (en) 2023-02-21
EP3972955A4 (en) 2023-07-05
TW202411205A (zh) 2024-03-16
KR20220011671A (ko) 2022-01-28
CN114008023B (zh) 2024-02-09
IL288285A (en) 2022-01-01
BR112021023241A2 (pt) 2022-01-04
TWI870116B (zh) 2025-01-11
MX2021014163A (es) 2022-01-04
JP6748329B1 (ja) 2020-08-26
EP3972955A1 (en) 2022-03-30
JP7605598B2 (ja) 2024-12-24
US20220298108A1 (en) 2022-09-22
PH12021552915A1 (en) 2022-04-04
MY206154A (en) 2024-12-02
WO2020235665A1 (en) 2020-11-26
US20210171460A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
JP7444957B2 (ja) ２－ヒドロキシ－６－（（２－（１－イソプロピル－１ｈ－ピラゾール－５－イル）ピリジン－３－イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
AU2020276695A1 (en) New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
TWI838531B (zh) 索吡銨溴化物的結晶形態及其製造方法
JP2018520205A (ja) レンバチニブメシル酸塩の新規結晶形及びその製造方法
WO2014008794A1 (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
CN119013267A (zh) 奥比塞匹布的盐及其制备方法和中间体
EA017483B1 (ru) Стабильная кристаллическая соль 1-азабицикло[2.2.2]окт-3-илового сложного эфира (r)-3-фторфенил-3,4,5-трифторбензилкарбаминовой кислоты
TWI745764B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
HUE030298T2 (en) (1,1-Dioxo-4-thiomorpholinyl) - [6 - [[3- (4-fluorophenyl) -5-methyl-4-isoxazolyl] methoxy] -3-pyridinyl] methanone
WO2024051771A1 (zh) 一种五元并六元杂环化合物的晶型及其制备方法和应用
CN110582279B (zh) 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物
HK40068368B (zh) 索吡溴铵的晶型及其制备方法
EP4501927A1 (en) Crystal of fused tricyclic derivative or pharmaceutically acceptable salt thereof
CN105712920B (zh) 一种维格列汀的制备方法
HK40068368A (en) Crystalline form of sofpironium bromide and preparation method thereof
CN121889375A (zh) 一种制备(R)-1,4-二氯-5-(甲基-d3)-6,7-二氢-5H-环戊[d]哒嗪的方法
CN114456109A (zh) 一种高纯度卡博替尼苹果酸盐的制备方法及其应用
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
HK40118106A (zh) 奥比塞匹布的盐及其制备方法和中间体
TW202313566A (zh) 製備氨磺必利之結晶型的方法
CN113683607A (zh) 一种特力利汀中间体晶型ii及其制备方法
KR20130125149A (ko) 나테글리니드의 신규한 결정형 및 이의 제조방법